The DOI matches its Crossref record; 142 of the 145 references it cites were found in a registry or an index; 20 of the 88 sources its claims cite were checked for support.
The Utility of Iron Chelators in the Management of Inflammatory Disorders
Open accessAbstract
Since iron can contribute to detrimental radical generating processes through the Fenton and Haber‐Weiss reactions, it seems to be a reasonable approach to modulate iron‐related pathways in inflammation. In the human organism a counterregulatory reduction in iron availability is observed during inflammatory diseases. Under pathological conditions with reduced or increased baseline iron levels different consequences regarding protection or susceptibility to inflammation have to be considered. Given the role of iron in development of inflammatory diseases, pharmaceutical agents targeting this pathway promise to improve the clinical outcome. The objective of this review is to highlight the mechanisms of iron regulation and iron chelation, and to demonstrate the potential impact of this strategy in the management of several acute and chronic inflammatory diseases, including cancer.
Overview
CoChat Summary
TL;DR
This review argues that iron-catalyzed reactive oxygen species contribute to acute and chronic inflammatory diseases, and that iron chelators may offer therapeutic benefit by sequestering redox-active iron. It surveys experimental and clinical evidence across cancer, atherosclerosis, diabetes/obesity, renal fibrosis, glaucoma, SIRS, ischemia-reperfusion injury, colitis, anemia, and iron overload/deficiency contexts, while noting risks and the need for better chelators.
Key findings
- Iron is essential but can catalyze ROS via Fenton and Haber-Weiss reactions; dysregulated iron homeostasis is linked to progressive inflammatory/degenerative diseases and cancer. The body contains approximately 3–4 g iron: hemoglobin accounts for 65%, ferritin/hemosiderin 25%, myoglobin/cytochromes/other enzymes 10%, and transferrin-bound iron about 0.1%; absorption is around 1 mg/day in men and 2 mg/day in women, and macrophage iron recycling is 20-fold greater than daily intestinal absorption.
- Inflammation triggers hypoferremia/anemia of inflammation through cytokines such as IL-6 and hepcidin; hepcidin binds ferroportin, causing its internalization and degradation, trapping iron in macrophages and hepatocytes and inhibiting intestinal iron absorption.
- Chelation studies report benefits in models: deferoxamine reduced adiposity via oxidative stress and inflammation in obese/type 2 diabetes KKAy mice, with only mild but not significant reductions in hemoglobin and hematocrit after two weeks; in UUO mice, deferoxamine reduced fibrotic progression, interstitial macrophage infiltration, IL-1β and MCP-1 expression, and myofibroblast accumulation; in pigs, deferoxamine attenuated lipid peroxidation, inhibited IL-6, and diminished SIRS and MOD; in rat colitis, highest-dose maltol was comparable to prednisolone and to deferoxamine/deferiprone.
- Clinical/contextual evidence notes that iron overload in hemochromatosis and thalassemia increases susceptibility to infections; the Pemba trial led to adverse events in children receiving iron in a malaria-endemic region; and in tuberculosis, iron supplementation increased mycobacterial growth and morbidity/mortality. New chelators designed to hold iron in a non-redox-active state may improve efficacy, whereas conventional chelators can be utilized by pathogens as iron sources.
Methods
- Narrative review whose objective was to highlight mechanisms of iron regulation and iron chelation and to demonstrate the potential impact of this strategy in several acute and chronic inflammatory diseases, including cancer.
- Data source: literature regarding experimental and clinical evidence for iron-related anti-inflammatory strategies; no primary patient cohort or systematic search strategy is described.
- Main analysis: qualitative synthesis of mechanistic pathways and disease-specific studies covering cancer, atherosclerosis, diabetes/obesity, renal fibrosis, glaucoma, SIRS, ischemia-reperfusion injury, colitis, anemia of inflammation, hereditary/acquired iron overload, and iron deficiency.
Limitations
- Stated: iron depletion as therapy is controversial because stored iron is often assumed to be inherently safe; the benefit of iron depletion can only be rigorously demonstrated in relation to iron in excess of needs; appropriate trials to rule out potential hazards of iron stores have not been undertaken; short-term harm such as anemia is possible; and conventional chelators may promote infection or be utilized by pathogens.
- Evident: as a narrative review, there is no systematic search, risk-of-bias assessment, or meta-analysis, and many experimental findings come from animal models while clinical evidence remains limited or observational.
- Evident: no primary data or sample size are reported, so efficacy conclusions are synthesized from heterogeneous studies rather than tested in a single controlled trial.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
13 Valid · 4 Not valid · 49 Not checked · 13 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Importantly, dysregulated iron homeostasis is associated with progressive inflammatory and degenerative diseases, as well as cancer [2].”
§ The Utility of Iron Chelators in the Management of Inflammatory Disorders > 1. Introduction
What the sources say
- Supportedcites [2] Kell D. B. Iron behaving badly: Inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases BMC Medical Genomics 2009 2, article 2 10.1186/1755-8794-2-2 2-s2.0-65449120792 PMC2672098 19133145 source
The Abstract > Review passage states the paper reviews 'the considerable and wide-ranging evidence for the involvement of this combination of (su)peroxide and poorly liganded iron in a large number of physiological and indeed pathological processes and inflammatory disorders, especially those involving the progressive degradation of cellular and organismal performance', covering cardiovascular, metabolic and neurological diseases and aging — i.e. progressive inflammatory and degenerative diseases. Section-level passages reinforce deranged iron metabolism in specific disorders (e.g. Psoriasis: 'clear evidence for the involvement of a deranged iron metabolism'; Diabetes: 'Serum ferritin and body iron stores are strongly associated with diabetes'; Neurodegeneration: 'Iron (and in some cases copper) is also strongly implicated in a variety of neurodegenerative diseases'). A dedicated 'Cancer and oncology' section links iron to oncogenesis (mutagenic Fenton chemistry, NGAL overexpression in tumours, iron restriction limiting tumour growth), so the cancer extension is also covered. The claim's hedged 'is associated with' is weaker than the paper's aetiological framing, which is acceptable. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Proinflammatory cytokines induced by inflammation can stimulate anemia of inflammation by limiting serum iron and increasing cellular iron stores by modulating the expression and activity of various iron regulatory proteins including hepcidin, FPN, ferritin, and the iron importer divalent metal transporter 1 (DMT1) [25–30].”
§ The Utility of Iron Chelators in the Management of Inflammatory Disorders > 2. Basic Mechanisms > 2.2. Iron and ROS
What the sources say
- Partly supportedcites [25] Nemeth E. Rivera S. Gabayan V. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin Journal of Clinical Investigation 2004 113 9 1271 1276 10.1172/JCI200420945 2-s2.0-2342510407 15124018 PMC398432 sourceExperimental — accuracy not yet measured
Our copy supports the core of the claim: the Abstract and Discussion state that IL-6 is 'the necessary and sufficient cytokine for the induction of hepcidin during inflammation' and that the IL-6-hepcidin axis causes the hypoferremia (limited serum iron) of anemia of inflammation, with the Introduction noting hepcidin inhibits release of recycled iron from macrophages and intestinal iron absorption (i.e., iron sequestration into cells). However, the paper does not support modulation of FPN (ferroportin) or DMT1 by proinflammatory cytokines — ferroportin/Ireg1 and DMT1 appear only in the titles of cited works in the References (refs 26, 29), and ferritin is mentioned only descriptively in the Introduction ('normal to elevated ferritin concentrations') as a feature of AI credited to ref 17, not as a cytokine-regulated target. So the hepcidin/serum-iron part is confirmed while the FPN, ferritin and DMT1 elements of the enumerated protein list are not attributable to this source. (LLM, conf=0.80)
- Partly supportedcites [26] Wrighting D. M. Andrews N. C. Interleukin-6 induces hepcidin expression through STAT3 Blood 2006 108 9 3204 3209 10.1182/blood-2006-06-027631 2-s2.0-33751175421 16835372 PMC1895528 sourceExperimental — accuracy not yet measured
Our copy supports the cytokine→hepcidin→low-serum-iron core of the sentence: the Introduction states hepcidin 'is a circulating hormone that is induced by inflammation, which blocks the release of iron from macrophages and interrupts intestinal iron absorption,' and that 'Administration of IL-6 to human subjects stimulates increased hepcidin production and results in low serum iron (hypoferremia) in vivo,' with the Abstract/Results establishing IL-6→STAT3 as the mechanism (this paper's own contribution). What this source does not support is the rest of the attribution: it never addresses modulation of ferroportin, ferritin, or DMT1 expression/activity (ferroportin appears only inside the title of a cited reference, Nemeth et al. 2004, ref. 2), nor does it report an increase in cellular iron stores. Searches for 'ferroportin/ferritin/divalent metal transporter 1' and for 'cellular iron stores/hypoferremia' returned no substantive passage. (LLM, conf=0.75)
- Partly supportedcites [27] Wang J. Song N. Jiang H. Xie J. Pro-inflammatory cytokines modulate iron regulatory protein 1 expression and iron transportation through reactive oxygen/nitrogen species production in ventral mesencephalic neurons Biochimica et Biophysica Acta—Molecular Basis of Disease 2013 1832 5 618 625 10.1016/j.bbadis.2013.01.021 2-s2.0-84874436258 23376588 sourceExperimental — accuracy not yet measured
Our copy supports the cellular-mechanism core: Section 3.1/3.2 and the Discussion (Figs. 1-2) show IL-1² or TNF-α upregulate DMT1+IRE and TfR1, downregulate FPN1 via IRP1, increase hepcidin mRNA (2.69- and 3.32-fold), and raise intracellular iron in ventral mesencephalic neurons. But the paper is an in vitro/MPTP mouse neuroscience study: no passage addresses anemia of inflammation, limiting serum iron, or ferritin modulation (ferritin appears only in the titles of cited refs 17 and 39), so those parts of the claim are not supported by this source. The hepcidin-STAT3 and FPN-internalization points in Section 3.2 are themselves credited to refs 27 and 28, though the paper reports its own hepcidin mRNA data. (LLM, conf=0.78)
- Partly supportedcites [28] Urrutia P. Aguirre P. Esparza A. Inflammation alters the expression of DMT1, FPN1 and hepcidin, and it causes iron accumulation in central nervous system cells Journal of Neurochemistry 2013 126 4 541 549 10.1111/jnc.12244 2-s2.0-84885953717 23506423 sourceExperimental — accuracy not yet measured
Urrutia et al. (2013) supports the cellular-arm of the claim: inflammatory stimuli (TNF-a, IL-6, LPS) increase DMT1 expression in neurons, astrocytes and microglia, induce hepcidin in astrocytes and microglia, and hepcidin decreases FPN1, with the net result of iron accumulation in neurons and microglia (Abstract; Discussion; Fig. 6 legend). However, our copy is a rat CNS cell study and contains nothing about anemia of inflammation or the systemic restriction of serum iron — it only refers to 'previous reports indicating that inflammatory stimuli induce the systemic synthesis of the master iron regulator hepcidin'. Ferritin is likewise not a finding here: it appears only as background ('the iron storage protein ferritin') and as another group's result (Hunter et al. 2008, increased ferritin expression after striatal LPS). The claim's 'and activity' extension is also unsupported — the paper measures expression/abundance and even notes that astrocytic iron efflux did not change despite decreased FPN1 (Rathore et al. 2012), and astrocytes showed no iron accumulation. (LLM, conf=0.78)
- Partly supportedcites [29] Rivera S. Liu L. Nemeth E. Gabayan V. Sorensen O. E. Ganz T. Hepcidin excess induces the sequestration of iron and exacerbates tumor-associated anemia Blood 2005 105 4 1797 1802 10.1182/blood-2004-08-3375 2-s2.0-13544252463 15479721 sourceExperimental — accuracy not yet measured
Our copy supports the hepcidin component of the claim: the Introduction states that inflammatory stimuli and IL-6 raise hepcidin, leading to hypoferremia and iron-refractory anemia, and the Chronic effects/Discussion show hepcidin lowering serum iron while sequestering iron in hepatocytes (Abstract; Chronic effects of hepcidin, p. 'It is often stated but not convincingly documented...'). However, the claim also attributes modulation of ferroportin (FPN), ferritin and DMT1 to this source, and no passage of our copy mentions any of those three proteins — searches for 'ferroportin', 'ferritin', 'divalent metal transporter 1/DMT1' returned only unrelated passages and reference-list entries. The unsupported part of the multi-citation sentence (25-30) is the FPN/ferritin/DMT1 modulation. (LLM, conf=0.78)
- Partly supportedcites [30] Atkinson S. H. Rockett K. A. Morgan G. Tumor necrosis factor SNP haplotypes are associated with iron deficiency anemia inWest African children Blood 2008 112 10 4276 4283 10.1182/blood-2008-06-162008 2-s2.0-61849125779 18716131 PMC2581977 sourceExperimental — accuracy not yet measured
Our copy supports much of the mechanism: the Introduction states TNF-alpha induces hypoferremia by inhibiting iron release from macrophage storage compartments and by transcriptional induction of ferritin, and the Discussion adds that TNF-alpha blocks intestinal iron absorption via enterocyte ferritin deposition and relocalization of ferroportin from the basolateral membrane. However, DMT1 is never mentioned anywhere in our copy (searched: DMT1, divalent metal transporter, ferroportin/hepcidin), and hepcidin appears only as a mechanism TNF-alpha acts INDEPENDENTLY of, not as a cytokine-modulated iron regulator; the paper's own data also concern iron deficiency/IDA in malaria-exposed Gambian children rather than anemia of inflammation. So the hepcidin and DMT1 elements of the attributed list, and the anemia-of-inflammation framing, are not supported by this source. (LLM, conf=0.78)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Oxidative stress may also modulate signal transduction pathways associated with malignancy [53].”
§ The Utility of Iron Chelators in the Management of Inflammatory Disorders > 4. Experimental Studies > 4.1. Cancer
What the sources say
- Supportedcites [53] Benhar M. Engelberg D. Levitzki A. ROS, stress-activated kinases and stress signaling in cancer EMBO Reports 2002 3 5 420 425 10.1093/embo-reports/kvf094 2-s2.0-0035984912 11991946 PMC1084107 source
The “ROS and cancer” section says ROS regulate cellular signaling, are elevated in cancer cells, and can affect transcription-factor and receptor-tyrosine-kinase signaling during tumor progression. This supports the hedged claim that oxidative stress may modulate malignancy-associated signaling pathways; page numbers were not supplied. (LLM, conf=0.93)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The authors concluded that in mice iron reduction by deferoxamine may prevent renal interstitial fibrosis by regulating TGF-beta/Smad signaling, oxidative stress, and inflammatory responses [67].”
§ The Utility of Iron Chelators in the Management of Inflammatory Disorders > 4. Experimental Studies > 4.4. Renal Fibrosis
What the sources say
- Supportedcites [67] Ikeda Y. Ozono I. Tajima S. Iron chelation by deferoxamine prevents renal interstitial fibrosis in mice with unilateral ureteral obstruction PLoS ONE 2014 9 2 e89355 10.1371/journal.pone.0089355 2-s2.0-84897786390 PMC3929716 24586712 source
The Discussion (opening paragraph) states that in UUO mice DFO suppressed renal interstitial fibrosis and collagen I/III/IV expression, prevented macrophage infiltration and inflammatory cytokine induction, and diminished oxidative stress via p22phox, concluding that 'the protective effect of iron chelation in UUO-induced renal interstitial fibrosis involves the inhibition of oxidative stress, inflammation, and pro-fibrotic signaling.' The Results section 'Effect of Reduced Iron Content on the TGF-β-Smad Signaling Pathway' reports DFO reducing UUO-induced TGF-β1 expression (to 77%) and phospho-Smad3 (to 76%), and the Discussion's closing sentence attributes the prevention to inhibiting oxidative stress and TGF-β1-Smad3 activation. The citing sentence's hedge ('may') is weaker than the source's own conclusion, so it is fully supported. (LLM, conf=0.92)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Interestingly, higher concentrations of free iron in breast cancer cells are associated with a more aggressive tumor phenotype [57].”
§ The Utility of Iron Chelators in the Management of Inflammatory Disorders > 4. Experimental Studies > 4.1. Cancer
What the sources say
- Supportedcites [57] Pinnix Z. K. Miller L. D. Wang W. Ferroportin and iron regulation in breast cancer progression and prognosis Science Translational Medicine 2010 2 43 43ra56 10.1126/scisignal.3001127 2-s2.0-77955607931 PMC3734848 20686179 source
The Results section 'Ferroportin reduction in breast cancer cells is associated with an increase in labile iron' states that breast cancer cells, expressing low ferroportin, had significantly higher labile (metabolically available/free) iron than normal breast epithelial cells (Fig. 1F). The Discussion ties that same alteration to aggressive behavior: the ferroportin reduction occurred 'particularly in the more aggressive and invasive areas of the cancer,' was 'sufficient to alter the LIP ... and to affect growth of tumor xenografts,' and the abstract links lowest ferroportin with highest anaplasia. The paper's own mechanistic model therefore is that elevated cellular free iron accompanies a more aggressive breast cancer phenotype; note the association with grade/outcome was measured on ferroportin, with the LIP measured in cell lines, and the authors hedge the causal role ('may play a previously unappreciated role'). (LLM, conf=0.82)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
39 more claims · 6 with their cited sources checked
Create a free account to see all 79 claims and to verify the 68 references still open.
- It may state two separate claims as one. 27
- Probably not a substantial claim. 9
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These chelators can alter the development of inflammatory diseases, have antiviral properties and can also be used in the treatment of malignancies (Meyer, 2006; Lehmann et al., 2015).”
From Iron at the Centre of Candida albicans Interactions (2018) · cites this paper as Lehmann et al., 2015
Experimental — accuracy not yet measured
Citations
Cites
Free radicals and antioxidants in normal physiological functions and human disease
Valko, M., Leibfritz, D., Moncol, J., Cronin, M. T. D., Mazur, M., & Telser, J. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2006.07.001 · Cited by 14,269 · cited 1×
“Low levels of ROS act as second messengers in many important signaling pathways, while prolonged exposure to higher levels can exceed cellular antioxidant defenses and damageDNA, lipids, and proteins [21, 23].”
BackgroundHepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization
Nemeth, E., Tuttle, M. S., Powelson, J., Vaughn, M. B., Donovan, A., Ward, D. M., Ganz, T., & Kaplan, J. (2004) · Science · doi:10.1126/science.1104742 · Cited by 4,803 · cited 2×
“Hepcidin is normally upregulated by excess iron stores [17].”
BackgroundWeiss, G., & Goodnough, L. T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041809 · Cited by 3,800
Nemeth, E., Rivera, S., Gabayan, V., Keller, C., Taudorf, S., Pedersen, B. K., & Ganz, T. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420945 · Cited by 2,650 · cited 1×
“To mitigate iron losses from the body from shedding of epithelial cells and menstruation, the body must absorb an equivalent amount of iron from the gut, maintaining an overall iron balance.”
BackgroundAndrews, N. C. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912233412607 · Cited by 2,130
Progress in Clinical and Biological Research
Smyth, J. F. (1979) · Journal of Clinical Pathology · doi:10.1136/jcp.32.7.742-d · Cited by 1,543
Iron Metabolism in Pathogenic Bacteria
Ratledge, C., & Dover, L. G. (2000) · Annual Review of Microbiology · doi:10.1146/annurev.micro.54.1.881 · Cited by 1,539 · cited 1×
“Both pathogenic bacteria [38] and fungi [39] can produce iron chelating siderophores as one strategy for obtaining host iron that is essential to their growth and pathogenesis [37, 39].”
BackgroundHepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein
Nemeth, E., Valore, E. V., Territo, M., Schiller, G., Lichtenstein, A., & Ganz, T. (2003) · Blood · doi:10.1182/blood-2002-10-3235 · Cited by 1,417
Dysmetabolic Hyperferritinemia: All Iron Overload Is Not Hemochromatosis
Makker, J., Hanif, A., Bajantri, B., & Chilimuri, S. (2015) · Case Reports in Gastroenterology · doi:10.1159/000373883 · Cited by 1,351
The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis
Donovan, A., Lima, C. A., Pinkus, J. L., Pinkus, G. S., Zon, L. I., Robine, S., & Andrews, N. C. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.01.003 · Cited by 1,275 · cited 7×
“It limits the cellular iron efflux by binding to FPN and facilitates its internalization and ultimate degradation [14].”
BackgroundInfluential
Cited by
COVID-19 as part of the hyperferritinemic syndromes: the role of iron depletion therapy
Perricone, C., Bartoloni, E., Bursi, R., Cafaro, G., Guidelli, G. M., Shoenfeld, Y., & Gerli, R. (2020) · Immunologic Research · doi:10.1007/s12026-020-09145-5 · Cited by 208
Iron at the Centre of Candida albicans Interactions
Fourie, R., Kuloyo, O. O., Mochochoko, B. M., Albertyn, J., & Pohl, C. H. (2018) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2018.00185 · Cited by 118
Kell, D. B., & Pretorius, E. (2018) · Biological reviews/Biological reviews of the Cambridge Philosophical Society · doi:10.1111/brv.12407 · Cited by 118
“…2015; Hansen, Moen & Mandrup-Poulsen, 2014; Jellen, Beard & Jones, 2009; Kell, 2009, 2010; Kell & Pretorius, 2014; Koskenkorva-Frank et al., 2013; Lehmann et al., 2015; Levi & Finazzi, 2014; Mollet et al., 2016; Muhoberac & Vidal, 2013; Muller & Leavitt, 2014; Nikonorov et al., 2015; Núñez et…”
Hezaveh, Z. S., Azarkeivan, A., Janani, L., Hosseini, S., & Shidfar, F. (2019) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2019.02.017 · Cited by 62
Chelators in Iron and Copper Toxicity
Lawson, M. K., Valko, M., Cronin, M., & Jomová, K. (2016) · Current Pharmacology Reports · doi:10.1007/s40495-016-0068-8 · Cited by 62
Metadata
- Authors
- Lehmann, C., Islam, S., Jarosch, S., Zhou, J., Hoskin, D., Greenshields, A., Al-Banna, N., Sharawy, N., Sczcesniak, A., Kelly, M., Wafa, K., Cheliak, W., & Holbein, B.
- Affiliations
- Dalhousie University (CA)
- Corresponding author
- Lehmann, C.
- Venue
- Mediators of Inflammation
- Publisher
- Wiley
- Published
- 2015-01
- Volume
- 2015
- Issue
- 1
- Pages
- 516740-516740
- ISSN
- 0962-9351 (ISSN-L)
- 1466-1861
- PMC
- PMC4386698
- OpenAlex
- W1974910643
- Cited by
- 54
- References
- 145
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 4 · 2023: 5 · 2022: 8 · 2021: 6 · 2020: 10 · 2019: 6 · 2018: 4 · 2017: 1 · 2016: 5
- FWCI
- 0.50
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Mediators of Inflammation (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
- Health Sciences › Nursing › Nutrition and Dietetics › Trace Elements in Health
- Keywords
- iron chelators, iron regulation, inflammation, Fenton reaction, Haber-Weiss reaction, iron availability, oxidative stress, chronic inflammatory diseases, acute inflammatory diseases, cancer
- MeSH terms
- Animals, Fibrosis, Hemochromatosis, Humans, Inflammation, Iron, Iron Chelating Agents, Kidney, Neoplasms, Reactive Oxygen Species, Systemic Inflammatory Response Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Utility of Iron Chelators in the Management of Inflammatory Disorders. https://app.cochat.ai/papers/10.1155/2015/516740
- The paper
- Lehmann, C., Islam, S., Jarosch, S., Zhou, J., Hoskin, D., Greenshields, A., Al-Banna, N., Sharawy, N., Sczcesniak, A., Kelly, M., Wafa, K., Cheliak, W., & Holbein, B. (2015). The Utility of Iron Chelators in the Management of Inflammatory Disorders. Mediators of Inflammation. https://doi.org/10.1155/2015/516740
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.